Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Dorling
Anthony Dorling, London GB
| Patent application number | Description | Published |
|---|---|---|
| 20100146648 | Immunosuppression by blocking T cell co-stimulation signal 2 (B7/CD28 interaction) - The invention provides means and methods for inhibiting T-cell mediated rejection of a xenotransplanted organ by blocking the delivery of co-stimulatory signal 2 (the B7/CD28 interaction) in order to prevent the activation of xenoreactive T-cells in the recipient. In a first aspect, co-stimulation is prevented by administration to the organ recipient of a soluble form of CTLA-4 from the xenogeneic donor organism. This preferentially binds B7 on the xenograft and blocks the interaction between B7 on the xenogeneic donor cells and CD28 on recipient T-cells. In a second aspect, co-stimulation is antagonised by expressing a ligand for CTLA-4 on the xenogeneic donor cells. This ligand binds to CTLA-4 on activated T-cells of the recipient and antagonises signal 2. In a third aspect, co-stimulation is prevented by expressing recipient organism MHC class II on the surface of the cells of the xenogeneic donor organ. The donor cells are thus able to present xenoantigens to a recipient T-cell in the context of self-MHC class II. If the donor cells do not express B7, or if B7 is blocked, the xenoreactive recipient T-cell becomes anergic. | 06-10-2010 |
Anthony Dorling US
| Patent application number | Description | Published |
|---|---|---|
| 20120017288 | Anticoagulant Fusion Protein Anchored to Cell Membrane - The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function is preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation). | 01-19-2012 |
Matthias Dorling, Grunbach DE
| Patent application number | Description | Published |
|---|---|---|
| 20100284827 | HOMOGENIZATION OF THE CONVEYING FLOW IN OSCILLATING POSITIVE DISPLACEMENT PUMPS - A method for homogenizing conveying flow from at least two oscillating positive displacement pumps utilizing a drive motor for each pump and a rotating shaft, the fluid conveying flow in a conveying line is generated by the oscillating positive displacement pumps, the drive motors controlled such that the conveying flow generated overall in the conveying line is largely uniform or constant. | 11-11-2010 |